Recently, glypican 3 (GPC3) has been evaluated as a sensitive marker for AFP-producing gastric carcinoma (GC) and its hepatoid component, and the authors support its usefulness for identifying this aggressive subgroup of GC [15]. This evidence concerns the gene AFP and gastric cancer.